The final session of the series Accelerating access to long-acting HIV prevention and treatment formulations and delivery platforms: Challenges and opportunities will discuss critical enablers that are needed to expedite access to at-scale manufacturing and supply of long-acting formulations and delivery platforms for HIV prevention and treatment, including the contribution of generic manufacturers. Lessons learned from scaling up access to HIV medicines and injectable contraceptives will be shared to inform how to prepare for roll out of long-acting formulations and delivery platforms at scale. Critical components that must be addressed in a timely and appropriate way will be discussed, including: affordability and the role and capacity of generic manufacturers; regulatory pathways and bioequivalence guidance; availability of clinical guidelines and their role to stimulate engagement from procurement agencies; demand creation and market size estimations and forecasts; and service delivery. Multiple stakeholders, including originator and generic manufacturers, procurement agencies, communities and civil society, will be invited to share their experiences.
The aim of the session is to: 1) reach a common understanding of the most critical enablers required to expedite at-scale access to long-acting formulations and delivery platforms of HIV prevention and treatment; 2) provide an update on the status of these enablers; and 3) share perspectives for the development of a roadmap to collectively address the most critical enablers.
